Last Updated: June 22, 2026

LISDEXAMFETAMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lisdexamfetamine, and what generic alternatives are available?

Lisdexamfetamine is a drug marketed by Actavis Elizabeth, Alkem Labs Ltd, Amneal, Apotex, Ascent Pharms Inc, Elite Labs Inc, Granules, Hikma, Lannett Co Inc, Mylan, Norwich, Prinston Inc, Rhodes Pharms, Sandoz, Specgx Llc, Sun Pharm Inds Inc, MSN, and Teva Pharms. and is included in twenty-two NDAs.

The generic ingredient in LISDEXAMFETAMINE is lisdexamfetamine dimesylate. Twenty-one suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lisdexamfetamine

A generic version of LISDEXAMFETAMINE was approved as lisdexamfetamine dimesylate by ACTAVIS ELIZABETH on August 25th, 2023.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for LISDEXAMFETAMINE?
  • What are the global sales for LISDEXAMFETAMINE?
  • What is Average Wholesale Price for LISDEXAMFETAMINE?
Summary for LISDEXAMFETAMINE
US Patents:0
Applicants:18
NDAs:22
Drug Prices: Drug price information for LISDEXAMFETAMINE
DailyMed Link:LISDEXAMFETAMINE at DailyMed
Drug patent expirations by year for LISDEXAMFETAMINE
Drug Prices for LISDEXAMFETAMINE

See drug prices for LISDEXAMFETAMINE

US Patents and Regulatory Information for LISDEXAMFETAMINE

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Norwich LISDEXAMFETAMINE DIMESYLATE lisdexamfetamine dimesylate CAPSULE;ORAL 214547-003 Aug 25, 2023 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Specgx Llc LISDEXAMFETAMINE DIMESYLATE lisdexamfetamine dimesylate CAPSULE;ORAL 211840-004 Aug 25, 2023 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Elite Labs Inc LISDEXAMFETAMINE DIMESYLATE lisdexamfetamine dimesylate CAPSULE;ORAL 218604-007 Nov 15, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ascent Pharms Inc LISDEXAMFETAMINE DIMESYLATE lisdexamfetamine dimesylate CAPSULE;ORAL 217442-005 Aug 25, 2023 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Rhodes Pharms LISDEXAMFETAMINE DIMESYLATE lisdexamfetamine dimesylate CAPSULE;ORAL 215330-003 Aug 25, 2023 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

DrugChatter Q&A for LISDEXAMFETAMINE
Lisdexamfetamine generic availability?
Lisdexamfetamine dimesylate?
Lisdexamfetamine dimesylate?
Lisdexamfetamine price increase 2025?
Sun pharma lisdexamfetamine?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links